Dashboard
Manage Tickers

CDTX Cidara Therapeutics, Inc.


$ 101.04 $ -0.96 (-0.95 %)    

Monday, 20-Oct-2025 19:01:50 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
$ 102.08
$ 96.68 x 10
$ 114.00 x 132
$ 97.85 - $ 103.00
$ 11.07 - $ 121.21
723,580
na
2.55B
$ 1.77
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

morgan-stanley-initiates-coverage-on-cidara-therapeutics-with-overweight-rating-announces-price-target-of-190
Morgan Stanley Initiates Coverage On Cidar...
10/16/2025 13:07:28

Morgan Stanley analyst Maxwell Skor initiates coverage on Cidara Therapeutics (NASDAQ:CDTX) with a Overweight rating and ann...

cidara-therapeutics-analyst-says-lead-influenza-candidate-is-strategically-attractive
Cidara Therapeutics Analyst Says Lead Infl...
10/10/2025 18:11:11

JP Morgan initiated coverage on Cidara Therapeutics with Overweight rating & tgt of $200, citing lead flu asset CD388's...

cidara-therapeutics-surges-ahead-of-eswi-2025-presentation-and-jp-morgan-coverage
Cidara Therapeutics Surges Ahead of ESWI 2...
10/10/2025 14:55:59

Cidara Therapeutics Inc (NASDAQ:CDTX) shares are trading higher on Friday after the biotech company made a recent announcement ...

cidara-therapeutics-to-present-cd388-navigate-phase-2b-influenza-data-at-eswi-2025-showcasing-cloudbreak-dfc-platform-in-late-breaking-abstract
Cidara Therapeutics To Present CD388 NAVIG...
10/10/2025 12:14:57

jp-morgan-initiates-coverage-on-cidara-therapeutics-with-overweight-rating-announces-price-target-of-200
JP Morgan Initiates Coverage On Cidara The...
10/10/2025 11:32:13

JP Morgan analyst Anupam Rama initiates coverage on Cidara Therapeutics (NASDAQ:CDTX) with a Overweight rating and announces...

wbb-securities-maintains-strong-buy-on-cidara-therapeutics-raises-price-target-to-199
WBB Securities Maintains Strong Buy on Cid...
10/09/2025 18:33:40

WBB Securities analyst Steve Brozak maintains Cidara Therapeutics (NASDAQ:CDTX) with a Strong Buy and raises the price targe...

hc-wainwright--co-maintains-buy-on-cidara-therapeutics-raises-price-target-to-150
HC Wainwright & Co. Maintains Buy on Cidar...
10/09/2025 14:50:58

HC Wainwright & Co. analyst Sara Nik maintains Cidara Therapeutics (NASDAQ:CDTX) with a Buy and raises the price target ...

fda-grants-breakthrough-therapy-designation-for-cidaras-cd388-for-preventing-influenza-a--b-in-high-risk-populations
FDA Grants Breakthrough Therapy Designatio...
10/09/2025 12:02:37

Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc ...

cidara-shares-are-trading-higher-friday-whats-going-on
Cidara Shares Are Trading Higher Friday: W...
10/03/2025 16:53:54

Cidara shares are trading higher Friday after the company secured $339 million in BARDA funding to advance its CD388 pandemic i...

jmp-securities-maintains-market-outperform-on-cidara-therapeutics-raises-price-target-to-173
JMP Securities Maintains Market Outperform...
10/03/2025 12:07:49

JMP Securities analyst Roy Buchanan maintains Cidara Therapeutics (NASDAQ:CDTX) with a Market Outperform and raises the pric...

cidara-secures-up-to-339m-barda-award-to-advance-cd388-pandemic-influenza-therapeutic-and-us-manufacturing
Cidara Secures Up To $339M BARDA Award To ...
10/02/2025 20:06:30

Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc ...

hc-wainwright--co-maintains-buy-on-cidara-therapeutics-raises-price-target-to-110
HC Wainwright & Co. Maintains Buy on Cidar...
09/26/2025 10:44:24

HC Wainwright & Co. analyst Sara Nik maintains Cidara Therapeutics (NASDAQ: CDTX) with a Buy and raises the price target...

cidara-therapeutics-announces-first-participants-dosed-in-phase-3-trial-to-evaluate-safety-and-efficacy-of-cd388-non-vaccine-preventative-of-seasonal-influenza-in-high-risk-populations
Cidara Therapeutics Announces First Partic...
09/25/2025 20:03:26

- Phase 3 study expected to enroll 6,000 participants starting in the Northern Hemisphere- Participants will include adults ove...

guggenheim-maintains-buy-on-cidara-therapeutics-raises-price-target-to-167
Guggenheim Maintains Buy on Cidara Therape...
09/25/2025 12:56:16

Guggenheim analyst Seamus Fernandez maintains Cidara Therapeutics (NASDAQ: CDTX) with a Buy and raises the price target from...

needham-maintains-buy-on-cidara-therapeutics-raises-price-target-to-100
Needham Maintains Buy on Cidara Therapeuti...
09/24/2025 16:10:22

Needham analyst Joseph Stringer maintains Cidara Therapeutics (NASDAQ:CDTX) with a Buy and raises the price target from $74 ...

wbb-securities-reiterates-strong-buy-on-cidara-therapeutics-maintains-123-price-target
WBB Securities Reiterates Strong Buy on Ci...
09/24/2025 11:22:28

WBB Securities analyst Steve Brozak reiterates Cidara Therapeutics (NASDAQ:CDTX) with a Strong Buy and maintains $123 price ...

cidara-therapeutics-announced-updates-to-its-planned-phase-3-registrational-trial-of-cd388-following-its-end-of-phase-2-meeting-with-fda
Cidara Therapeutics Announced Updates To I...
09/24/2025 11:09:04

Cidara is proceeding with an expanded and accelerated development plan seeking biologics license application (BLA) approval bas...

wbb-securities-maintains-strong-buy-on-cidara-therapeutics-raises-price-target-to-123
WBB Securities Maintains Strong Buy on Cid...
09/22/2025 12:13:12

WBB Securities analyst Steve Brozak maintains Cidara Therapeutics (NASDAQ:CDTX) with a Strong Buy and raises the price targe...

cidara-therapeutics-presents-data-on-cd388-from-phase-2b-navigate-trial-and-preclinical-studies-against-h5n1
Cidara Therapeutics Presents Data On CD388...
09/17/2025 12:05:06

- Efficacy and safety results from successful NAVIGATE Phase 2b trial of CD388 for prevention of influenza illness featured in ...

cidara-therapeutics-to-present-two-oral-sessions-including-late-breaking-at-isrv-avg-and-imrp-meetings
Cidara Therapeutics To Present Two Oral Se...
09/03/2025 12:06:58

Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION